Last reviewed · How we verify
Terpenes-Enriched CBD-Predominant Oil
Terpenes-Enriched CBD-Predominant Oil is a Small molecule drug developed by Bazelet Nehushtan LtD.. It is currently in Phase 2 development.
At a glance
| Generic name | Terpenes-Enriched CBD-Predominant Oil |
|---|---|
| Sponsor | Bazelet Nehushtan LtD. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Terpenes-Enriched CBD-Predominant Oil CI brief — competitive landscape report
- Terpenes-Enriched CBD-Predominant Oil updates RSS · CI watch RSS
- Bazelet Nehushtan LtD. portfolio CI
Frequently asked questions about Terpenes-Enriched CBD-Predominant Oil
What is Terpenes-Enriched CBD-Predominant Oil?
Terpenes-Enriched CBD-Predominant Oil is a Small molecule drug developed by Bazelet Nehushtan LtD..
Who makes Terpenes-Enriched CBD-Predominant Oil?
Terpenes-Enriched CBD-Predominant Oil is developed by Bazelet Nehushtan LtD. (see full Bazelet Nehushtan LtD. pipeline at /company/bazelet-nehushtan-ltd).
What development phase is Terpenes-Enriched CBD-Predominant Oil in?
Terpenes-Enriched CBD-Predominant Oil is in Phase 2.